INGN
Inogen Inc
NASDAQ · Healthcare · Medical - Devices · US
$6.55
+4.80%Year over year
Reported trailing growth
- Revenue
- +3.2%
- EBITDA
- +39.1%
- EBIT
- +9.2%
- EPS
- +15.1%
- Free cash flow
- +56.7%
- Operating cash flow
- +70.3%
Forward estimates
Based on analyst estimates
- Revenue
- +3.1%
- EBITDA
- +187.4%
- EPS
- +41.1%
Three-year CAGR
- Revenue
- -2.6%
- EBITDA
- +82.4%
- EBIT
- +29.0%
- Net income
- +36.6%
- EPS
- +44.1%
- Free cash flow
- -93.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026